Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (2016 - 2026)

Gyre Therapeutics has reported Shares Outstanding over the past 16 years, most recently at $91.3 million for Q4 2025.

  • Quarterly Shares Outstanding rose 5.8% to $91.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.3 million through Dec 2025, up 5.8% year-over-year, with the annual reading at $91.3 million for FY2025, 5.8% up from the prior year.
  • Shares Outstanding was $91.3 million for Q4 2025 at Gyre Therapeutics, roughly flat from $90.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $91.3 million in Q4 2025 and troughed at $31.3 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $63.6 million (2021), against an average of $64.3 million.
  • Year-over-year, Shares Outstanding soared 187.76% in 2021 and then changed 0.0% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $63.6 million in 2021, then changed by 0.0% to $63.6 million in 2022, then rose by 20.46% to $76.6 million in 2023, then increased by 12.68% to $86.3 million in 2024, then increased by 5.8% to $91.3 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Shares Outstanding are $91.3 million (Q4 2025), $90.9 million (Q3 2025), and $90.8 million (Q2 2025).